I was just hoping that my on-line submitted question regarding Canadian reimbursement for Daybue would not be squeezed out of a mountain of questions. Turns out it was the only one, so I’m as surprised as you.
Jon mentioned that the reimbursement negotiations with the authority is for the public sector only, so it seems as though it won’t affect the private sector for the launch. However does anyone know roughly what the private vs public sector ratio is regarding the Canadian Daybue market opportunity?
A solid AGM update. Awesome to have clarity that Neuren will seek going straight to Phase 2/3 for HIE. Not unexpected though given the established safety profile of NNZ2591, and I suspect this route is also likely for the remaining undisclosed opportunities. I am reassured and content to be heavily overweight in Neuren.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)